

1 Exploring plasma cell motility and extracellular matrix protein biomarkers for primary progressive
2 multiple sclerosis: A pilot study

3

4 Exploring extracellular matrix proteins as MS progression biomarkers

5

6

7 Elijah Lackey^{1*}

8 Stephanie Reinke¹

9 Sheng Luo²

10 Daniel Laskowitz³

11 Christopher Eckstein¹

12 Simon G Gregory^{1, 4}

13

14 ¹ Division of MS & Neuroimmunology, Department of Neurology, Duke University, Durham, NC, United
15 States of America

16 ² Division of Biostatistics, Department of Biostatistics & Bioinformatics, Duke University, Durham, NC,
17 United States of America

18 ³ Division of Neurocritical Care, Department of Neurology, Duke University, Durham, NC, United States
19 of America

20 ⁴ Department of Neurosurgery, Duke University, Durham, NC, United States of America

21

22

23 * Corresponding author: Elijah Lackey, MD Elijah.lackey@duke.edu (EL)

24

25

26

27

28 **Abstract**

29 Primary progressive multiple sclerosis is associated with neurodegeneration and chronic inflammation,

30 and results in the accumulation of gradual disability. This pilot study investigated 92 plasma proteins

31 using proximal extension assay to identify MS subtype-specific biomarkers with a focus on predicting
32 primary progressive MS. We analyzed samples from 66 MS patients (22 relapsing-remitting, 22
33 secondary progressive, and 22 primary progressive) and 22 controls. ANOVA identified five proteins
34 (ACAN, TMSB10, BST1, CLEC11A, MYOC) with $p < 0.05$ for differentiating phenotypes of MS, four of
35 which have been previously implicated in MS pathophysiology. However, after correcting for multiple
36 comparisons no individual proteins remained statistically significant. Logistic regression and support
37 vector models using these 5 proteins for predicting primary progressive, in one-vs all-models, against
38 other MS phenotypes and controls were of low accuracy (0.69 and 0.68, respectively). While not
39 immediately translatable, these results lay the groundwork for future studies into MS progression
40 biomarkers.

41 **Introduction**

42 Multiple sclerosis (MS) is the most common autoimmune disease affecting the central nervous system.
43 (1) MS causes both inflammatory relapses and a more insidious neurodegeneration referred to as
44 progression. Recently, a paradigm shift has occurred in our understanding of disability accumulation in
45 MS with the knowledge that progression contributes to disability accrual more than relapses.(2, 3)
46 Multiple high-efficacy MS disease modifying therapies are available that effectively prevent relapses, but
47 their effect on progression remains poorly understood. Because of this new focus on progression as a
48 clinical target, there is greater need for disease-specific biomarkers that can monitor its development
49 and track its severity.

50 Current blood biomarkers, such as neurofilament light chain and glial fibrillary acidic protein, can be
51 increased by a wide variety of neurologic diseases.(4, 5) This lack of specificity has prevented their
52 widespread clinical use for managing MS. Similarly, although some cerebrospinal fluid biomarkers such
53 as SERPINA3 have shown promise, they are not practical for tracking disease activity longitudinally.(6)

54 New disease and progression specific blood biomarkers will need to be discovered to translate
55 effectively to the clinic.

56 In this pilot study, we targeted plasma proteins previously implicated in MS pathophysiology to identify
57 specific markers of progression (Table 1). The panel we selected includes many proteins previously
58 hypothesized to play a role in MS pathophysiology, neurodegeneration, or remyelination. We explored
59 whether individual proteins or a group of proteins from this panel could distinguish between MS
60 phenotypes and used selected proteins in a predictive model for primary progressive MS. Primary
61 progressive MS was chosen as the phenotype of interest because these patients experience the greatest
62 degree of progression.(3) A commercially available panel of proteins (Olink Development Target 96,
63 Olink Waltham, MA) was selected that focuses on cell migration and extracellular matrix organization.
64 such as Laminin A4, Aggrecan, and PARK7 (S1 Table).(7, 8, 9)

65

66 **Materials and methods**

67 Duke University IRB exemption was obtained (Pro00112531). Samples were obtained from adult
68 patients (age >18) who participated in the MURDOCK (Measurement to Understand Reclassification of
69 Disease Of Cabarrus and Kannapolis) study diagnosed with secondary progressive (SP), primary
70 progressive (PP) or relapsing remitting (RR) MS. The MS cohort includes 25 PP patients, 88 SP patients,
71 and 966 RR patients. Controls were derived from the greater MURDOCK study, which includes 12,526
72 patients. Samples were collected and stored (-80C) in a standardized process for the MURDOCK
73 repository from 3/2009 to 8/2016. Clinical data was accessed August 4th, 2023. The authors did not have
74 access to identifiable data for participants either before or after data collection. EDTA plasma samples
75 were matched by age, sex, disease modifying therapy, and race (1:1:1:1). We excluded patients
76 with recent radiographic relapse or treatment with steroids (within 30 days). MS diagnosis and relapses
77 were self-reported by patients. Sample analysis was performed using Olink proximal extension assay,

78 which provides a semi-quantitative measure of protein concentration called NPX (Normalized
79 Protein eXpression) relative to controls. NPX units are the inverse of cyclic threshold (Ct) on a log2scale,
80 which means the NPX value increases with greater protein concentrations. We ran 22 samples per
81 group, each from a unique individual, for a total of 88 samples. We randomized samples across the 96
82 well plate. The kit was run with internal controls, negative controls, and sample controls.
83 The Olink platform has a standard quality control process involving four internal controls that were
84 added to each sample to monitor assay performance and quality of individual samples. The sample plate
85 was evaluated on the standard deviation to the internal controls. Samples that deviated less than 0.3
86 NPX from the median passed quality control. Primary statistical analysis was performed using one-way,
87 balanced ANOVA on a per-protein basis. Bonferroni correction was applied to account for multiple
88 comparisons. With 22 independent samples in each of the 4 groups, evaluating 92 proteins in each
89 sample, we expected to detect an effect size of 0.55 with a power of 0.82 and an adjusted p-value of
90 0.0005. Proteins found to differentiate PP vs other subtypes of MS by ANOVA (p value < 0.05) were
91 included in logistic regression and support vector machine models. We split pre-processed data into a
92 training set (80%) and test set (20%). We performed 5-fold cross-validation to assess the performance of
93 each model. Receiver operator curves were generated for the models and the area under the curve was
94 calculated to measure performance of each model. Statistical analysis was done in Python (base 3.11.4)
95 in a Jupyter notebook.

96 Results

97 Samples were matched for age, sex, disease-modifying therapy (for MS patients), and race (Table 1).

	Primary Progressive	Secondary Progressive	Relapsing Remitting	Controls
Age, mean (SD)	57.4 (8.8)	53.8 (9.9)	49.9 (9.4)	49.6 (9.7)

Female Sex, n (%)	12 (54.5)	17 (77.3)	18 (81.8)	15 (68.1)
Most Common DMT	Interferon Beta-1a	Interferon Beta-1a	Glatiramer acetate	none
Race, n (%)				
<i>White/Caucasian</i>	18 (81.8)	20 (90.9)	18 (81.8)	19 (86.4)
<i>Black/African American</i>	4 (18.2)	2 (9.1)	4 (18.1)	3 (13.6)

98

99 Table 1. Summary statistics after matching on age, sex, MS disease-modifying therapy, and race.

100 After randomization across the plate, samples were analyzed per the Olink platform protocol. All

101 samples and assays met the platform's quality control measures. ANOVA resulted in five proteins;

102 aggrecan (ACAN), thymosin beta-10 (TMSB10), ADP-ribosyl cyclase (BST1), C-type lectin domain family

103 11 member A (CLEC11A), and myocilin (MYOC) with p-values less than 0.05. Although none of the

104 proteins remaining statistically significant after Bonferroni correction (adjusted p value 0.0005), five

105 proteins of interest were incorporated into logistic regression and support vector machine models

106 comparing on an all-vs-one basis (PP vs all other groups including control). Logistic regression yielded an

107 accuracy of 0.69 and the support vector machine an accuracy of 0.68 (Fig 1).

108

109 Fig 1. Receiver operating characteristic curves and accuracies for the support vector and logistic
110 regression models

111 Discussion

112 As clinical priorities for the care of patients with MS shift toward a focus on progression, we need better

113 biomarkers to quantify disease activity. We now know that progression plays a pivotal role in MS-

114 related disability accrual.(3) This new perspective has sparked a need for more specific and readily

115 accessible biomarkers to monitor and differentiate the extent of progression among MS patients. The

116 choice of blood biomarkers in our study was deliberate, as they offer practicality and clinical utility. We

117 refrained from revisiting well-established markers of neuronal injury and instead focused on a

118 commercially available panel of proteins, Olink Development Target 96, that included multiple disease-
119 specific proteins in order to improve the specificity of our results.

120 Our primary analysis yielded five proteins, namely aggrecan (ACAN), thymosin beta-10 (TMSB10), ADP-
121 ribosyl cyclase (BST1), C-type lectin domain family 11 member A (CLEC11A), and myocilin (MYOC), with
122 p-values below 0.05. Each of these were increased in PP vs other MS types except for myocilin (Fig 2).

123

124 Fig 2. Concentrations of proteins by normalized protein expression units (NPX) found to distinguish the
125 three MS subtypes ($p < 0.05$) comparing RR grouped with SP vs PP. Each protein was increased in PP vs
126 RR/SP except for myocilin.

127 However, after applying Bonferroni correction for multiple comparisons, none of these proteins
128 remained statistically significant. To determine whether these 5 proteins might serve as biomarkers for
129 predicting primary progressive MS we incorporated them into logistic regression and support vector
130 machine models. These models attempted to distinguish PP from all three other groups (RR, SP,
131 controls). Unsurprisingly, given our small sample size, these models had low accuracy (0.69 and 0.75
132 respectively).

133 It is important to note that four out of the five proteins; aggrecan (ACAN), ADP-ribosyl cyclase (BST1),
134 thymosin beta-10 (TMSB10), and C-type lectin domain family 11 member A (CLEC11A), have previously
135 been implicated in MS pathophysiology or in remyelination. ACAN, a proteoglycan, is known to be
136 upregulated in MS lesions and may interfere with remyelination, while also playing a role in
137 neurodegeneration. (8, 10, 11) BST1, thought to be involved with B cell maturation, may be upregulated
138 when cognitive dysfunction is present in pediatric MS.(12) TMSB10, a member of the thymosin proteins,
139 is part of a class of proteins that may regulate remyelination.(13) CLEC11A, a secreted sulfated
140 glycoprotein acting on C-Type Lectin Receptors (CLRs), has been implicated in experimental autoimmune
141 encephalomyelitis (EAE) pathogenesis.(14) Myocilin (MYOC), to our knowledge, has not been previously

142 studied in MS disease pathophysiology. MYOC is a multimeric secreted glycoprotein that may affect
143 leukocyte adhesion to endothelium.(15) Its specific role in the context of MS requires further
144 exploration.

145 Our study has several limitations. Its reliance on self-reported MS diagnoses, based on outdated
146 diagnostic criteria, is certainly a limitation. The relatively small sample size is also a constraint to be
147 considered. Future studies with larger cohorts and samples from patients with more recent diagnoses,
148 using the latest diagnostic criteria, are needed to advance our understanding of MS progression and to
149 discover disease-specific biomarkers.

150 **Conclusions**

151 This pilot study provides a preliminary exploration into plasma biomarkers for MS progression, with a
152 specific focus on biomarkers predictive of primary progressive MS. Five proteins were identified; ACAN,
153 BST1, TMSB10, CLEC11A, and MYOC that differentiate subtypes of MS with $p < 0.05$. While none of the
154 individual proteins achieved statistical significance after correction for multiple comparisons, these
155 proteins show potential for further investigation. Importantly, myocilin (MYOC) is a secreted
156 glycoprotein that has not previously been implicated in MS pathophysiology or investigated as a
157 biomarker. The need for further research to validate and expand upon these findings remains pressing,
158 particularly in the context of emerging treatments targeting MS progression.

159

160 **Acknowledgments**

161 This work was made possible through the use of the MURDOCK Study and Duke University's CTSA grant
162 (UL1TR002553) from the National Institutes of Health (NIH)'s National Center for Advancing
163 Translational Sciences (NCATS).

164
165
166

Supporting Information

S1 Table. Proteins from the Olink Target 96 Development Panel Implicated in MS or EAE Pathophysiology

Biologic Function	Protein and references
Extracellular Matrix Proteins	Laminin A4 (7)
	Aggrecan (8, 10)
	Matrilin-2 (16)
B cell Differentiation and Regulation	Fc receptor-like protein 5 (17, 18, 19)
	Macrophage migration inhibitory factor (20)
	HLA class II histocompatibility antigen gamma chain (CD74) (20)
	ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 (BST1) (12)
Leukocyte adhesion and migration	Lymphocyte function-associated antigen 3 (CD58) (21)
	CD99 antigen-like protein 2 (CD99L2) (22)
	C-C motif chemokine 21 (CCL21) (23, 24)
Mitochondrial homeostasis and antioxidant defenses	CD177 antigen (CD177) (25)
	CD97 (26)
	PARK7 (9)
Angiogenesis	HTRA2 (27)
	PDGFRB (28, 29)
Lysosomal degradation	LGMN (30)

167
168
169

Supplemental Table 1. Proteins in the Olink Target 96 Development Panel with prior evidence for involvement in experimental autoimmune encephalomyelitis (EAE) or multiple sclerosis (MS).



170
171
172
173
174
175
176
177

1. Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, et al. The prevalence of MS in the United States: A population-based estimate using health claims data. *Neurology*. 2019;92(10):e1029-e40.
2. Tur C, Carbonell-Mirabent P, Cobo-Calvo A, Otero-Romero S, Arrambide G, Midaglia L, et al. Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis. *JAMA Neurol*. 2023;80(2):151-60.


- 178 3. Lublin FD, Haring DA, Ganjgahi H, Ocampo A, Hatami F, Cuklina J, et al. How patients with
179 multiple sclerosis acquire disability. *Brain*. 2022;145(9):3147-61.
- 180 4. Abdelhak A, Foschi M, Abu-Rumeileh S, Yue JK, D'Anna L, Huss A, et al. Blood GFAP as an
181 emerging biomarker in brain and spinal cord disorders. *Nat Rev Neurol*. 2022;18(3):158-72.
- 182 5. Shahim P, Politis A, van der Merwe A, Moore B, Ekanayake V, Lippa SM, et al. Time course and
183 diagnostic utility of NfL, tau, GFAP, and UCH-L1 in subacute and chronic TBI. *Neurology*.
184 2020;95(6):e623-e36.
- 185 6. Fissolo N, Matute-Blanch C, Osman M, Costa C, Pinteac R, Miro B, et al. CSF SERPINA3 Levels Are
186 Elevated in Patients With Progressive MS. *Neurol Neuroimmunol Neuroinflamm*. 2021;8(2).
- 187 7. van Horssen J, Dijkstra CD, de Vries HE. The extracellular matrix in multiple sclerosis pathology. *J*
188 *Neurochem*. 2007;103(4):1293-301.
- 189 8. Keough MB, Rogers JA, Zhang P, Jensen SK, Stephenson EL, Chen T, et al. An inhibitor of
190 chondroitin sulfate proteoglycan synthesis promotes central nervous system remyelination. *Nat*
191 *Commun*. 2016;7:11312.
- 192 9. Vavougiou GD, Zarogiannis SG, Krogfelt KA, Gourgoulis K, Mitsikostas DD, Hadjigeorgiou G.
193 Novel candidate genes of the PARK7 interactome as mediators of apoptosis and acetylation in multiple
194 sclerosis: An in silico analysis. *Mult Scler Relat Disord*. 2018;19:8-14.
- 195 10. Lin JZ, Duan MR, Lin N, Zhao WJ. The emerging role of the chondroitin sulfate proteoglycan
196 family in neurodegenerative diseases. *Rev Neurosci*. 2021;32(7):737-50.
- 197 11. Pu A, Stephenson EL, Yong VW. The extracellular matrix: Focus on oligodendrocyte biology and
198 targeting CSPGs for remyelination therapies. *Glia*. 2018;66(9):1809-25.
- 199 12. Liguori M, Nuzziello N, Simone M, Amoroso N, Viterbo RG, Tangaro S, et al. Association between
200 miRNAs expression and cognitive performances of Pediatric Multiple Sclerosis patients: A pilot study.
201 *Brain Behav*. 2019;9(2):e01199.
- 202 13. Severa M, Zhang J, Giacomini E, Rizzo F, Etna MP, Cruciani M, et al. Thymosins in multiple
203 sclerosis and its experimental models: moving from basic to clinical application. *Mult Scler Relat Disord*.
204 2019;27:52-60.
- 205 14. N'Diaye M, Brauner S, Flytzani S, Kular L, Warnecke A, Adzemovic MZ, et al. C-type lectin
206 receptors Mcl and Mincle control development of multiple sclerosis-like neuroinflammation. *J Clin*
207 *Invest*. 2020;130(2):838-52.
- 208 15. Aroca-Aguilar JD, Fernandez-Navarro A, Ontanon J, Coca-Prados M, Escribano J. Identification of
209 myocilin as a blood plasma protein and analysis of its role in leukocyte adhesion to endothelial cell
210 monolayers. *PLoS One*. 2018;13(12):e0209364.
- 211 16. Jonas A, Thiem S, Kuhlmann T, Wagener R, Aszodi A, Nowell C, et al. Axonally derived matrilin-2
212 induces proinflammatory responses that exacerbate autoimmune neuroinflammation. *J Clin Invest*.
213 2014;124(11):5042-56.
- 214 17. Chorazy M, Wawrusiewicz-Kurylonek N, Adamska-Patrano E, Czarnowska A, Zajkowska O,
215 Kapica-Topczewska K, et al. Variants of Novel Immunomodulatory Fc Receptor Like 5 Gene Are
216 Associated With Multiple Sclerosis Susceptibility in the Polish Population. *Front Neurol*. 2021;12:631134.
- 217 18. Comabella M, Canto E, Nurtdinov R, Rio J, Villar LM, Picon C, et al. MRI phenotypes with high
218 neurodegeneration are associated with peripheral blood B-cell changes. *Hum Mol Genet*.
219 2016;25(2):308-16.
- 220 19. Yuan M, Wei L, Zhou R, Bai Q, Wei Y, Zhang W, et al. Four FCRL3 Gene Polymorphisms (FCRL3_3,
221 _5, _6, _8) Confer Susceptibility to Multiple Sclerosis: Results from a Case-Control Study. *Mol Neurobiol*.
222 2016;53(3):2029-35.
- 223 20. Meza-Romero R, Benedek G, Yu X, Mooney JL, Dahan R, Duvshani N, et al. HLA-DRalpha1
224 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis. *J*
225 *Immunol*. 2014;192(9):4164-73.

- 226 21. De Jager PL, Baecher-Allan C, Maier LM, Arthur AT, Ottoboni L, Barcellos L, et al. The role of the
227 CD58 locus in multiple sclerosis. *Proc Natl Acad Sci U S A*. 2009;106(13):5264-9.
- 228 22. Samus M, Seelige R, Schafer K, Sorokin L, Vestweber D. CD99L2 deficiency inhibits leukocyte
229 entry into the central nervous system and ameliorates neuroinflammation. *J Leukoc Biol*.
230 2018;104(4):787-97.
- 231 23. Dhaiban S, Al-Ani M, Elemam NM, Maghazachi AA. Targeting Chemokines and Chemokine
232 Receptors in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. *J Inflamm Res*.
233 2020;13:619-33.
- 234 24. Bielecki B, Jatczak-Pawlik I, Wolinski P, Bednarek A, Glabinski A. Central Nervous System and
235 Peripheral Expression of CCL19, CCL21 and Their Receptor CCR7 in Experimental Model of Multiple
236 Sclerosis. *Arch Immunol Ther Exp (Warsz)*. 2015;63(5):367-76.
- 237 25. Cordiglieri C, Baggi F, Bernasconi P, Kapetis D, Faggiani E, Consonni A, et al. Identification of a
238 gene expression signature in peripheral blood of multiple sclerosis patients treated with disease-
239 modifying therapies. *Clin Immunol*. 2016;173:133-46.
- 240 26. Visser L, de Vos AF, Hamann J, Melief MJ, van Meurs M, van Lier RA, et al. Expression of the EGF-
241 TM7 receptor CD97 and its ligand CD55 (DAF) in multiple sclerosis. *J Neuroimmunol*. 2002;132(1-2):156-
242 63.
- 243 27. Maus F, Sakry D, Biname F, Karram K, Rajalingam K, Watts C, et al. The NG2 Proteoglycan
244 Protects Oligodendrocyte Precursor Cells against Oxidative Stress via Interaction with OMI/HtrA2. *PLoS*
245 *One*. 2015;10(9):e0137311.
- 246 28. Iacobaeus E, Sugars RV, Tornqvist Andren A, Alm JJ, Qian H, Frantzen J, et al. Dynamic Changes in
247 Brain Mesenchymal Perivascular Cells Associate with Multiple Sclerosis Disease Duration, Active
248 Inflammation, and Demyelination. *Stem Cells Transl Med*. 2017;6(10):1840-51.
- 249 29. Sekerdag-Kilic E, Ulusoy C, Atak D, Ozkan E, Gokyuzu AB, Seyaj S, et al. Perivascular PDGFRB+
250 cells accompany lesion formation and clinical evolution differentially in two different EAE models. *Mult*
251 *Scler Relat Disord*. 2023;69:104428.
- 252 30. Huynh JL, Garg P, Thin TH, Yoo S, Dutta R, Trapp BD, et al. Epigenome-wide differences in
253 pathology-free regions of multiple sclerosis-affected brains. *Nat Neurosci*. 2014;17(1):121-30.

254



Figure



Figure